Fruquintinib as Maintenance Therapy After Adjuvant Chemotherapy in Advanced Colorectal Cancer with NED

The overall 5-year survival rate for patients with colorectal liver metastases (CRLM) remains below 20%. While surgery and adjuvant therapy can lead to no evidence of disease (NED), over 60% of patients experience recurrence. To address this, this study investigates the clinical effectiveness and safety of fruquintinib as maintenance therapy in patients with advanced CRC who have achieved NED after completing adjuvant chemotherapy. Fruquintinib, a highly selective small molecule anti-angiogenic inhibitor, has the potential to reduce tumor recurrence and prolong the time to recurrence and metastasis when used in this setting. The CSCO guidelines already include fruquintinib as a level I recommendation for third-line therapy in CRC. This study aims to further evaluate its role in improving long-term outcomes for patients with advanced CRC.